Peptidream
VC Fund
Tokyo, Japan
PeptiDream is a biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System (PDPS), a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective hitcandidates, which then can be developed into peptide-based, small molecule-based, or peptide-drug-conjugate-based therapeutics.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Peptidream invests in
Stages Peptidream invests in
Countries Peptidream invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Hiroaki Suga
|
|||
Keiichi Masuya
|
|||
Kiyofumi Kaneshiro
|
|||
Patrick C. Reid
|
|||
Shinichiro Fujiie
|
Investment Focus
Industry
- Pharmaceutical 3 (50%)
- Medical 2 (33%)
- Health Care 2 (33%)
- Oncology 1 (17%)
- Biotechnology 1 (17%)
Stage
- Series A 2 (33%)
- Series B 2 (33%)
- Corporate Round 1 (17%)
Country
- Japan 3 (50%)
- United States 1 (17%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Hiroaki Suga
Co-Founder
|
Co-Founder | Total investments: 0 | Find email | |
|
Keiichi Masuya
COO
|
COO | Total investments: 2 | Find email | |
|
Kiyofumi Kaneshiro
Executive Vice President Director – Board Member
|
Executive Vice President Director – Board Member | Total investments: 2 | Find email | |
|
Patrick C. Reid
Co-Founder, President & CEO
|
Co-Founder, President & CEO | Total investments: 0 | Find email | |
|
Shinichiro Fujiie
Director, Executive Officer
|
Director, Executive Officer | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Linqmed
|
Linqmed is a pharmaceutical company that specializes in the research and development of radiopharmaceuticals for cancer treatment. | $15.9M / Series B / Apr 09, 2025 | |
|
Linqmed
|
Linqmed is a pharmaceutical company that specializes in the research and development of radiopharmaceuticals for cancer treatment. | $9.5M / Series B / Jan 10, 2025 | |
|
Linqmed
|
Linqmed is a pharmaceutical company that specializes in the research and development of radiopharmaceuticals for cancer treatment. | $4.8M / Series A / Dec 22, 2023 | |
Kleo
|
Kleo is developing two types of small molecules to treat cancer, infectious diseases, and a broad range of indications: Antibody Recruiting Molecules (ARMs) and Synthetic Antibody Mimics (SyAMs). They believe their technology represents a breakthrough in safer, more efficacious, and more convenient treatment options. | $21M / Series B / Nov 14, 2018 | |
Alivexis
|
Modulus Discovery is a private Tokyo-based preclinical stage drug discovery company focused on rapid design and generation of small molecule clinical candidates for a range of high-value disease targets through the use of its cutting-edge computational drug discovery expertise and unique biology insights. The international team at Modulus iscomprised of drug design and disease biology experts with previous R&D experience at global pharmaceutical, biotechnology , and computational technology firms. | $7.2M / Series A / Aug 09, 2018 | |
PeptiStar
|
PeptiStar is a CDMO (Contract Development and Manufacturing Organization) for peptide APIs, from traditional peptides to constrained peptides including macrocyclic and stapled peptides containing non-natural amino acids. PeptiStar is a technology-based company that provides its customers with high value-added services through its innovativemanufacturing technologies. | $186.3M / Corporate Round / Apr 18, 2018 |
Co-Investors
DBJ Capital
4 deals together
JIC Venture Growth Investments
2 deals together
Mizuho Capital
2 deals together
Axil Capital
1 deal together
Biohaven Pharmaceutical
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Peptidream invest in?
Peptidream invests primarily in Pharmaceutical, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Peptidream?
Public channels for Peptidream include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Peptidream?
The team at Peptidream includes Hiroaki Suga (Co-Founder), Keiichi Masuya (COO) and Kiyofumi Kaneshiro (Executive Vice President Director – Board Member). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
